New msds

MATERIAL SAFETY DATA SHEET
N/A = Not Applicable
(Prepared According To 29 CFR 1910.1200)
Effective Date: 11/09
SECTION 1 - PRODUCT IDENTIFICATION
Product Name:
NPCA Hazardous Materials
Chemical Family: N/A
Identification System
Generic Name: Disinfectant deoderant.
Formula: N/A
Suppliers Name: SUPERIOR CHEMICAL CORP.
Flammability
Suppliers Address: 1331 Wisconsin Avenue, Sheboygan, WI 53081
Reactivity
Phone: 800-242-7694
Maximum Personal Protection
EMERGENCY PHONE: 800-535-5053
SECTION 2 - HAZARDOUS INGREDIENTS
CHEMICAL NAME
PEL TWA-TLV
STEL-TLV CARCINOGEN
SECTION 3 - PHYSICAL DATA
SECTION 4 - FIRE & EXPLOSION HAZARD DATA
Boiling Range (˚F): 176°F
Specific Gravity: 0.83
Flash Point (method used): 76°F (TCC)
Vapor Pressure: 31
Vapor Density:
Upper Explosive Limit: Not det. Not det.
Lower Explosive Limit:
% Volatile: N / A
Extinguishing Media: Carbon dioxide, dry chemical or foam.
Solubility in Water: Soluble
Evaporation Rate:
Special Fire Fighting Procedures: Wear full protective gear.
Physical Description: Clear light yellow liquid with a floral scent.
Unusual Fire & Explosion Hazards: Container may melt.
VOC's: 4.940 lbs/gal.
SECTION 5 - REACTIVITY DATA
SECTION 6 - STORAGE & HANDLING INFO
Stability: Stable
Hazardous Polymerization: Will not occur.
Precautions To Be Taken In Handling & Storage:
Incompatibility (materials to avoid): Strong acids and oxidizers.
Keep out of reach of children. For use by trained personnel only. Keep container closed during storage. For institutional and industrial use only.
Hazardous Decomposition Products: Carbon dioxide. carbon monoxide
SECTION 7 - HEALTH HAZARDS AND FIRST AID
Effects of Overexposure
First Aid
Primary Route of Entry:
Procedures:
Skin: Prolonged exposure may cause irritation or dryness.
Skin: Wash well with soap and water. Seek medical attention if
Eyes: Irritant.
Eyes: Irrigate for 15 minutes minimum. Seek medical attention.
Inhalation: Dizziness, nausea, stomach ache and anorexia. Irritation
Inhalation: Remove to fresh air.
Ingestion: See first aid procedures.
Ingestion: DO NOT INDUCE vomiting. Seek medical attention
Persons medicated with ANTABUSE will have adverse reactions SECTION 8 - SPECIAL PROTECTION INFORMATION
Respiratory Protection: Use in adequate ventilation.
Ventilation: Provide local exhaust to keep TLV of Section 2 ingredients
Protective Gloves: Yes.
Other Protective Equipment:As needed to prevent direct contact.
Eyes: Yes.
SECTION 9 - SPILL OR LEAK PROCEDURES
Steps to be taken in case material is released or spilled:
Waste disposal method:
Mop up or otherwise absorb and hold material for disposal.
Any method in accordance with applicable laws.
Notice to reader: To the best of our knowledge, the information contained herein is accurate. However, neither the above named supplier nor any of its subsidiaries assumes anyliability whatsoever for the accuracy or completeness of the information contained herein. Final determination of suitability of any material is the sole responsibility of the user.
All material may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazardsthat exist. **FOR FURTHER INFORMATION OR TO DOWNLOAD ADDITIONAL MSDS GO TO www.northwoodstm.com ** The health hazards given on this Material Safety Data Sheet apply to this product in its concentrated form (as supplied) and may differ significantly at use dilution. The signs and symptomsof overexposure apply only to negligence in handling or misuse of the concentrated product and not to the routine exposure of the diluted product underconditions or ordinary use.

Source: http://northwoodstm.com/resources/MSDS/Megacide.pdf

ordiniveterinaripiemonte.it

A CASE OF THE CHRONIC FATIGUE SYNDROME IN A HORSE FROM USA EXAMINED IN DUBAI (UAE). Author: W. Tarello , DVM, C.P. 1644, 06129 PERUGIA 5 (ITALY) Accepted for Poster presentation at the THIRD INTERNATIONAL CLINICAL AND SCIENTIFIC MEETING: Chronic Fatigue Syndrome, a serious legitimate diagnosis. Sydney, 1-2 December 2001. ABSTRACT - A six-year old castrated male warm-blood horse with a two-year

Polyfarmacie optimalisatie methode

Polyfarmacie Optimalisatie Methode (POM) De Polyfarmacie Optimalisatie Methode (POM) is een stappenplan dat gebruikt kan worden om op een gestructureerde wijze ingewikkelde polyfarmacie te optimaliseren. De eerste twee stappen van de POM kunnen door een daartoe aangewezen praktijkondersteuner uitgevoerd worden. De stappen 3 en 4 moeten door de (huis)arts uitgevoerd worden. Voor de stappen 5

Copyright © 2010 Find Medical Article